Ask AI

2026 Oncology Nursing Virtual Day of Education

 
Virtual Simulcast
 
In-Person
 
Free CME/CE Credits

2026 Oncology Nursing Virtual Day of Education

Join us for a dynamic day of education designed specifically for APPs and nurses, featuring expert-led sessions across hematologic and solid tumor malignancies, including:

  • Practical insights into the integration and management of bispecific antibodies in multiple myeloma
  • Evidence-based strategies for adverse event monitoring and supportive care in chronic-phase CML
  • Exploring the evolving role of the multidisciplinary team in optimizing outcomes for patients with HER2-negative metastatic breast cancer
  • Reviewing valuable guidance on recognizing, monitoring, and managing acute, delayed, and long-term adverse events associated with CAR T-cell therapy

Through interactive discussions, real-world case applications, and actionable clinical guidance, this day of education will leave you better equipped to bring back immediately applicable strategies to your clinical practice.

 

Date
Varies per Event

 

Time
Varies per Event
Timezone Converter ›

 

Location
Virtual

Event Schedule

Claim Credit

To claim credit, click the link below, complete the evaluation, and you'll be given access to your certificate.

Multiple Myeloma CP-CML HER2-Negative MBC CAR T-Cell Therapy

Featured Faculty

Faculty

Amy Goodrich, RN, MSN, CRNP

  • Nurse Practitioner
  • Johns Hopkins Kimmel Cancer Center
  • Baltimore, Maryland
Faculty

Ashley Martinez, PhD, DNP, APRN, FNP-BC, AOCNP, CPHQ, NEA-BC, NPD-BC

  • Director, Advanced Practice
  • Advanced Practice Programs
  • The University of Texas MD Anderson Cancer Center
  • Houston, Texas
Faculty

Tiffany Richards, PhD, ANP-BC, AOCNP

  • Nurse Practitioner
  • Myeloma APP Manager
  • Department of Lymphoma/Myeloma
  • MD Anderson Cancer Center
  • Houston, Texas
Faculty

Stephany L. Rodriguez, NP, MS, RN

  • Nurse Practitioner
  • Hematology, Oncology, Blood and Marrow Transplant and Cellular Therapy
  • Specialty Coordination, Oncology APP Fellowship
  • University of California, San Francisco
  • San Francisco, California

Accreditation

From Target to Tolerability: Nurse-Led Strategies for Optimizing Bispecific Antibody Therapy in Multiple Myeloma

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

  • Care of the Pediatric Hematology and Oncology Patient (CPHON) - 0.75*
  • Foundations of Transplant/HSCT and Cellular Therapy (TCTCN) - 0.75*
  • Oncologic Emergencies (OCN, CPHON, AOCNP) - 0.5*
  • Oncology Nursing Practice (OCN) - 0.75*
  • Pediatric Hematology Oncology Nursing Practice (CPHON) - 0.75*
  • Professional Practice/Performance (TCTCN, AOCNP, ROCN) - 0.25*
  • Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP) - 0.5*
  • Treatment (AOCNP, CBCN, CPHON, OCN, ROCN) - 1.0*

Total Points: 1.0*

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of ILNA points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Disclosure of Conflicts of Interest

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Accreditation

Advances in Personalized TKI Therapy for CP-CML: Nursing Considerations to Enhance Patient Education, Tolerability, and Adherence

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC dba Decera Clinical Education and CLL Society. Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

  • HSCT and Cellular Therapy Process and Administration (TCTCN) - 0.25*
  • Oncology Nursing Practice (OCN) - 0.25*
  • Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP) - 0.25*
  • Treatment (AOCNP, CBCN, CPHON, OCN, ROCN) - 1.0*

Total Points: 1.0*

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of ILNA points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Disclosure of Conflicts of Interest

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Accreditation

Navigating HER2-Negative MBC: An Oncology Nurse Roadmap to Maximize Efficacy and Enhance Tolerability With Antibody–Drug Conjugates

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

  • Care Continuum (OCN, CBCN, CPHON, AOCNP, ROCN) - 0.25*
  • Nursing Practice (CBCN) - 0.25*
  • Oncology Nursing Practice (OCN) - 0.25*
  • Psychosocial Dimensions of Care (AOCNP, CPHON, OCN, CBCN) - 0.25*
  • Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP) - 0.75*
  • Treatment (AOCNP, CBCN, CPHON, OCN, ROCN) - 1.0*

Total Points: 1.0*

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of ILNA points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Disclosure of Conflicts of Interest

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Accreditation

CAR T-Cell Therapy in Community and Shared-Care Settings: Practical Strategies to Manage Delayed and Long-term Toxicities

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Disclosure of Conflicts of Interest

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

From Target to Tolerability: Nurse-Led Strategies for Optimizing Bispecific Antibody Therapy in Multiple Myeloma
Provided by Clinical Care Options, LLC dba Decera Clinical Education.
Supported by an educational grant from Johnson & Johnson.

Advances in Personalized TKI Therapy for CP-CML: Nursing Considerations to Enhance Patient Education, Tolerability, and Adherence
Provided by Clinical Care Options, LLC dba Decera Clinical Education.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Navigating HER2-Negative MBC: An Oncology Nurse Roadmap to Maximize Efficacy and Enhance Tolerability With Antibody–Drug Conjugates
Provided by Clinical Care Options, LLC dba Decera Clinical Education.
This activity is supported by an educational grant from Gilead Sciences, Inc.

CAR T-Cell Therapy in Community and Shared-Care Settings: Practical Strategies to Manage Delayed and Long-term Toxicities
Provided by Clinical Care Options, LLC dba Decera Clinical Education.
This activity is supported by educational grants from Bristol Myers Squibb and Johnson & Johnson.